Rapid and potent C5 inhibition achieved with complete and sustained blockage of complement by a single dose of CAN106 Data to be presented at the 14th International Conference on Complement
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. The .